Myelofibrosis (MF; primary or post-essential thrombocythemia/ polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II study to evaluate the activity of DNA methyltransferase inhibitor, 5-azacitidine, in patients with MF. Thirty-four patients (76% previously treated) received 5-azacitidine at 75 mg/m 2 subcutaneously daily for 7 days, every 4 weeks. Twelve (35%) patients had abnormal cytogenetics and 19 (70%) of 27 evaluable patients had JAK2 V617F mutation. Responses occurred in 8 (24%) patients after a median of 5 months (range, 3-10). Partial response occurred in 1 (3%) patient (duration 22 þ months) and clinical improvement in 7 (21%) patients (median duration 4 months; range, 2-8.5). Myelosuppression was the major adverse effect, with grade 3-4 neutropenia in 10 (29%) patients. Global DNA methylation assessed by the long interspersed nucleotide element (LINE) bisulfite/pyrosequencing assay decreased from 53% pretherapy to 44% on day 14 (P ¼ 0.0014) and returned to 50% at the end of the first 28-day cycle (P ¼ 0.016). 5-azacitidine is relatively well tolerated and results in induction of global hypomethylation in patients with MF, but results in limited clinical activity.
Introduction
Myelofibrosis (MF; primary or post-essential thrombocythemia/ polycythemia vera) is a stem cell-derived clonal myeloproliferative disorder characterized by ineffective hematopoiesis, bone marrow fibrosis and extramedullary hematopoiesis. Neither drug therapy nor allogeneic stem-cell transplantation has been shown to prolong survival in MF. 1 The lack of efficacious therapies for MF is a direct consequence of the limited knowledge of the molecular underpinnings of this disorder. A dominant gain-of-function G4T point mutation resulting in the substitution of phenylalanine for valine at position 617 in Janus kinase 2 (JAK2) has been recently described in patients with myeloproliferative disorders. [2] [3] [4] [5] [6] The JAK2 V617F mutation represents the first acquired somatic mutation in hematopoietic stem cells described in these disorders. The incidence of the JAK2 V617F mutation in patients with MF, as determined by allele-specific PCR, ranges from 35 to 50%. 2, 5 Several small-molecule therapeutics targeting the JAK2 V617F mutation are currently under preclinical and clinical development. In addition to genetic alterations, epigenetic events, such as aberrant CpG island hypermethylation in regulatory areas of tumor suppressor genes leading to their inactivation, have been frequently implicated in the pathogenesis of human cancer. 7 For instance, methylation of p15 INK4B , p16
INK4A and the retinoic acid receptor b has been reported in advanced stages of MF. 8, 9 Reversibility of epigenetic changes through pharmacologic manipulation with DNA hypomethylating agents has rendered encouraging results in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia. These results have laid the groundwork for the development of active epigenetic approaches for other malignancies. 5-azacitidine (azacitidine; Vidaza, Pharmion, Boulder, CO, USA) and 5-aza-2 0 -deoxycitidine (decitabine; Dacogen, MGI Pharma Inc., Bloomington, MN, USA) are DNA methyltransferase inhibitors that induce reactivation of methylated genes. 10, 11 Both agents have been approved by the Food and Drug Administration for the treatment of patients with MDS. 12, 13 We herein report on the results of a first phase-II trial specifically designed to test the efficacy of 5-azacitidine in patients with either relapsed/refractory MF or newly diagnosed MF with poor prognosis.
Patients and methods

Eligibility
Patients at least 18 years of age with MF (according to the World Health Organization criteria, revised in 2001) requiring therapy, including those previously treated, relapsed, or refractory or if newly diagnosed with intermediate or high-risk (that is score 1-2) MF according to the Lille scoring system (risk factors are: Hbo10 g per 100 ml, WBCo4 or 430 Â 10 9 /l; risk groups: 0 factors ¼ low, 1 factor ¼ intermediate, 2 factors ¼ high) were eligible. Other eligibility criteria included: (1) performance status p2 by the ECOG scale; (2) serum creatinine level o1.5 mg per 100 ml; (3) serum bilirubin level p1.5 times the upper limit of the normal range; (4) patients were required to be off chemotherapy for 2 weeks before entering the study and have recovered from the toxic effects of that therapy (patients were allowed to enter the study on stable dose of anagrelide and/or hydroxyurea, for at least 4 weeks before study entry, to control high platelet and WBC counts); (5) women of childbearing potential were required to practice effective methods of contraception. All patients signed an informed consent form approved by the institutional review board.
Treatment schedule
Patients received initially 5-azacitidine at 75 mg/m 2 subcutaneously, daily for 7 days, every 4 weeks (dose level 0). After the administration of the first course, the dose of 5-azacitidine for subsequent courses could be delayed up to 8 weeks, or modified, based on adverse events (dose level À1: 50 mg/m 2 , dose level À2: 25 mg/m 2 , dose level À3: 12.5 mg/m 2 ). Patients with stable disease were allowed to continue on therapy until definite evidence of disease progression or a maximum of six courses; those with signs of a clinical benefit after six courses, as judged by treating physicians, were allowed to continue therapy for a maximum of 18 courses. 5-azacitidine was allowed to be escalated by one dose level (dose level þ 1: 100 mg/m 2 ), if response was not satisfactory after 2 courses, provided that no grade 3-4 toxicity was observed. Patients developing grade 1-3 non-hematologic toxicity could have received a subsequent course at the same dose but recovery to grade 0-1 was required before institution of the next course. In the event of drug-related grade 4 non-hematologic toxicity, 5-azacitidine was given at one reduced dose level after resolution of toxicity to grade 0-1. Patients who developed grade 4 hematologic toxicity, defined as X75% reduction in absolute neutrophil count or platelet count from the pretreatment value for more than 2 consecutive weeks, resumed therapy at one lower dose level. A reduction of 2 dose levels was considered if myelosuppression was deemed severe and/or life threatening by the treating physician. As a general rule, a subsequent course of therapy was administered when absolute neutrophil count was X1.0 Â 10 9 /l (or X50% of the pretreatment value) and platelets were X50 Â 10 9 /l (or X50% of the pretreatment value).
Toxicities were evaluated using the revised National Cancer Institute Common Toxicity Criteria version 2.0.
Patient evaluation
Baseline studies included a complete physical examination, complete blood count, comprehensive biochemistry panel (including liver function tests) and bone marrow aspirate with cytogenetics, and molecular test for JAK2 V617F mutation. JAK2 V617F mutation status was determined based on previously published methods.
14 A complete blood count with differential and blood chemistries were obtained weekly for the first two courses, and then every 2 weeks while on therapy. Bone marrow biopsy and aspirate were performed every two courses for the first six courses, then for every two to four courses. Cytogenetics and JAK2 V617F mutation analysis were performed (if abnormal pretherapy) at those time points on a bone marrow aspirate, whenever this was successfully obtained. Otherwise, JAK2 V617F mutation analysis was performed on bone marrow biopsy specimens. In this study, the use of growth factors was allowed. However, response criteria (Table 1 ) required patients to be off anagrelide, hydroxyurea, growth factors and not receiving transfusions for at least 8 weeks (according to response criteria). The criteria used in this study have been developed by the International Working Group for Myelofibrosis Research and Therapy (IWG-MRT). 15 
Study design
The present study was a prospective open-label, single center, phase-II trial with a Gehan's modified two-stage design. The primary efficacy endpoint of the study was objective clinical response. We deemed reasonable to assume that a response rate of 20% would warrant further investigation of the study medication in MF. A total of 14 patients were enrolled in a first stage. At least one response had to be observed among the first 14 patients to suggest a therapeutic effect with a 5% error rate for rejecting an active drug. The achievement of one response permitted the accrual of 20 additional patients in a second stage, for a total of 34 study subjects. The statistical analysis for response rates was determined on an intention-totreat basis.
DNA bisulfite treatment and bisulfite pyrosequencing for LINE methylation
Peripheral blood was collected on days 0, 7, 14, 21 and 28 during the first cycle of 5-azacitidine from consenting patients as part of this protocol. We used a long interspersed nucleotide Table 1 International working group for myelofibrosis research and therapy (IWG-MRT) criteria for response in patients with myelofibrosis
Response category Criteria
Complete remission (CR) (i) Complete resolution of disease-related symptoms and signs, including palpable hepatosplenomegaly.
(ii) Peripheral blood count remission, defined as hemoglobin level at least 11 g per 100 ml, platelet count at least 100 Â 10 9 per 100 ml and ANC at least 1.0 Â 10 9 per 100 ml. In addition, all three blood counts should be no higher than the upper normal limit. (iii) Normal leukocyte differential including disappearance of nucleated red blood cells, blasts and immature myeloid cells in the peripheral smear, in the absence of splenectomy. (iv) Bone marrow histologic remission defined as the presence of age-adjusted normocellularity, no more than 5% myeloblasts and an osteomyelofibrosis grade no higher than 1.
Partial remission (PR)
Requires all of the above criteria for CR except the requirement for bone marrow histologic remission. However, a repeat bone marrow biopsy is required in the assessment of PR and may or may not show favorable changes that do not, however, fulfill criteria for CR Clinical improvement (CI)
Requires one of the following in the absence of both disease progression (as outlined below) and CR/PR assignment (CI response is validated only if it lasts for no fewer than 8 weeks): (i) A minimum 2 g per 100 ml increase in hemoglobin level or becoming transfusion independent (applicable only for patients with baseline hemoglobin level of less than 10 g per 100 ml).
(ii) Either a minimum 50% reduction in palpable splenomegaly of a spleen, that is, at least 10 cm at baseline or a spleen that is palpable at more than 5 cm at baseline becomes not palpable. (iii) A minimum 100% increase in platelet count and an absolute platelet count of at least 50 Â 10 9 per 100 ml (applicable only for patients with baseline platelet count below 50 Â 10 9 per 100 ml). (iv) A minimum 100% increase in ANC and an ANC of at least 0.5 Â 10 9 per 100 ml (applicable only for patients with baseline ANC below 1 Â 10 9 per 100 ml).
Abbreviations: ANC: absolute neutrophil count; WBC: white blood cell. Progressive disease requires either (i) progressive splenomegaly defined by the appearance of a previously absent splenomegaly that is palpable at greater than 5 cm below the left costal margin or a minimum 100% increase in palpable distance for baseline splenomegaly of 5-10 cm or a minimum 50% increase in palpable distance for baseline splenomegaly of greater than 10 cm; (ii) leukemic transformation confirmed by a bone marrow blast count of at least 20% or (iii) an increase in peripheral blood blast percentage of at least 20% for at least 8 weeks.
Activity of 5-azacitidine in myelofibrosis
A Quintás-Cardama et al element (LINE) bisulfite pyrosequencing assay to estimate global methylation. 10, 16 After bisulfite treatment, PCR was carried out in a 50 ml solution containing 60 mmol/l tris-HCl pH ¼ 8.8, 15 mM ammonium sulfate, 0.5 mmol/l MgCl 2 , 1 mM dNTP mix and 1 unit of Taq polymerase. The primer sequences employed in PCR and sequencing were as follows: LINE-F2: TTTTGAGTTA GGTGTGGGATATA, LINE-R2: AAAATCAAAAAATTCCCTTTC and LINE-S: GGGTGGGAGTGAT. The final biotin-labeled PCR product was captured by Streptavidin Sepharose HP (Amersham Biosciences, Uppsala, Sweden). PCR product bound on the bead was purified and made single stranded in a Pyrosequencing Vacuum Prep Tool (Pyrosequencing Inc., Westborough, MA, USA). Sequencing primer was annealed to a singlestranded PCR product and pyrosequencing was performed using the PSQ HS 96 Pyrosequencing system (Biotage AB, Uppsala, Sweden). Quantification of cytosine methylation was performed using the PSQ HS96A 1.2 software package.
Results
Patient characteristics
A total of 34 patients (13 female and 21 male) were enrolled between June 2005 and May 2006 ( Table 2 ). The Lille score for the 34 patients, at the time of the enrollment, was 0 for 16 patients, 1 for 11 patients and 2 for 7 patients. Before 5-azacitidine, patients had received a median of one therapy (range 0-6) for MF, including hydroxyurea (n ¼
Response to 5-azacitidine
The median duration of 5-azacitidine therapy was 5.5 months (range, 2-18). Responses have been observed in 8 (24%) patients (Table 3 ). The median time to response was 5 months (range, [3] [4] [5] [6] [7] [8] [9] [10] . No complete remission was observed. One (3%) patient met all criteria for complete remission except for the achievement of bone marrow histologic remission and, therefore, categorized as having a partial remission, which has been maintained for 22 þ months. In addition, 7 (21%) patients achieved clinical improvement durable for a median of 4 months (range, 2-8.5). Clinical improvement was achieved by 2 (13%) of 15 patients with Hbo10 g per 100 ml or transfusion-dependent, 4 (24%) of 17 patients with a spleen that was palpable at more than 5 cm at baseline and by 1 (25%) of 4 patients with absolute neutrophil counto1 Â 10 9 per 100 ml. No patients had improvement of bone marrow reticulin or collagen fibrosis. Five of the eight responders had received prior therapies (including four who had received myelosuppressive therapy) and three were untreated previously (Table 3) . Responses were observed both in patients with (one partial remission, four clinical improvement) and without (one clinical improvement) the JAK2 V617F mutation (JAK2 V617F mutational Activity of 5-azacitidine in myelofibrosis A Quintás-Cardama et al status was not determined in two responders). 5-azacitidine therapy did not affect the JAK2 V617F status (percentage of mutation positive cells in bone marrow) in any patient carrying this mutation and only reduced the proportion of clones harboring cytogenetic abnormalities in two out of five responders with abnormal karyotype (Table 3) . No correlation between particular patients' characteristic and a response to therapy has been found.
To date, all responses have been lost except for that of a 74-year-old woman with post-polycythemic MF of 2 years duration, who achieved a partial remission. This patient started 5-azacitidine therapy with WBC count 26.5 Â 10 9 per 100 ml, Hb 9.8 g per 100 ml (transfusion-dependent), platelet count 144 Â 10 9 per 100 ml, enlarged spleen at 12 cm and abnormal cytogenetics (46XX, þ 1,der(1;7)(q10;p10)). Although the degree of reticulin fibrosis in the bone marrow has not changed significantly and the JAK2 V617F mutation burden decreased only from 93.8 to 84.5%, she continues to be in partial remission of 22 þ months duration. More important, this response has been maintained for 10 þ months off 5-azacitidine therapy.
Toxicity
A total of 142 cycles of 5-azacitidine were administered to 34 patients and the main toxicities are shown in Table 4 . Fourteen (41%) patients experienced a total of 18 episodes of grade 3-4 toxicity, being the most frequent anemia, fatigue, nausea, arthalgia, neutropenia and neutropenic fever. Sixteen (47%) patients required 5-azacitidine dose reductions, including 14 (41%) patients who had their dose reduced to 50 mg/m 2 (dose level À1), and 2 (6%) who had their dose reduced to 25 mg/m 2 (dose level À2). In addition, 6 (18%) patients had the 5-azacitidine dose increased to 100 mg/m 2 (dose level þ 1). One patient died after experiencing cardiac arrest unrelated to the study drug and another one, with grade 4 thrombocytopenia before receiving 5-azacitidine, had a subdural hematoma during the first course of therapy that was successfully managed conservatively. To date, only 1 (3%) patient remains on study. Thirty-three (97%) patients discontinued 5-azacitidine due to loss of response (n ¼ 10), lack of response (n ¼ 7), grade 3-4 toxicity (n ¼ 6), transformation to acute myeloid leukemia (n ¼ 2), allogeneic stem-cell transplant (n ¼ 1), death (n ¼ 1), patient's decision (n ¼ 1) and intercurrent medical reasons (n ¼ 5).
Analysis of DNA methylation during 5-azacitidine therapy
We also analyzed that the effect of 5-azacitidine therapy on global methylation of genomic DNA was by using a LINE1 bisulfite pyrosequencing assay as a surrogate of global DNA methylation (Figure 1) . DNA from patient blood was obtained before treatment (day 0), immediately following 5-azaciditine administration (day 7), 1 week after the last dose of 5-azacitidine (day 14) and at days 21 and 28 from the start of 5-azacitidine treatment. Genomic DNA methylation was evaluated in Table 4 Adverse events related to therapy with 5-azacitidine
Number of patients (%) Figure 1a ). Similar to the experience reported in patients with MDS, 17 therapy with 5-azacitidine resulted in gradual and significant decline of the levels of LINE methylation from the baseline, 53 ± 0.56% (mean±s.e.m.), during 5-azacitidine therapy. This decline persisted for 7 days after the last dose of 5-azacitidine on day 7 (48±0.81%), achieving a nadir by day 14 of the first cycle (44 ± 3.25%). After day 14, LINE re-methylation was observed (44±1.11% on day 21) but the level was not completely back to baseline before the following course of therapy (50 ± 0.86% on day 28). Notably, the degree of global DNA hypomethylation achieved during treatment was not different between responders and non-responders. However, a trend towards a more rapid hypomethylating effect in responders was observed at day 7 of the treatment with 5-azacitidine (P ¼ 0.11).
Discussion
Cytosine methylation is an epigenetic phenomenon that has been correlated with loss of expression of tumor suppression genes, thereby, providing a selective advantage to neoplastic cells. 7 Hypermethylation of the promoter region of tumor suppressor genes is a well-characterized epigenetic change in human cancer and this has spurred the testing of DNA methyltransferase inhibitors as anticancer and differentiation agents. 18 The nucleoside analogue, 5-azacitidine, is a potent inhibitor of DNA methylation in vitro.
11 5-azacitidine-induced DNA hypomethylation results upon stoichiometric binding of this agent to DNA methyltransferase 1. 19 In the present study, we report the results of the first trial of hypomethylating therapy for patients with MF. Overall, responses were observed in 24% of patients. Notably, responses were observed among patients with poor-risk cytogenetics and in those carrying the JAK2 V617F mutation. 5-azacitidine was generally well tolerated, although more than 40% of patients experienced grade 3-4 toxicity that required dose reduction in 47% of the cases. Nevertheless, premature deaths related to therapy did not occur.
Molecular correlative studies were performed to evaluate the effect of 5-azacitidine on DNA methylation in samples from patients. We confirmed that 5-azacitidine had hypomethylating activity in vivo as assessed by LINE bisulfite pyrosequencing assay in peripheral blood samples. Consistent with in vitro data, 5-azacitidine induced global DNA hypomethylation that reached its nadir by day 14 after the first dose of the drug (7 days after the last dose of the drug). Then, re-methylation was observed, although this did not return fully to baseline by day 28, before the administration of the next 5-azacitidine course. As previously reported in patients with MDS treated with hypomethylating agents, we did not observe difference in global hypomethylation between responders and non-responders. However, LINE methylation is a phenomenon that can be observed in both normal and neoplastic cells, indicating that the analysis of the dynamics of DNA methylation with the LINE assay must be interpreted as a surrogate marker of the biological activity of 5-azacitidine independent from its clinical activity. In fact, it can be argued that the activity observed with 5-azacitidine may not be completely related to the induction of DNA hypomethylation. Moreover, it is unclear why responding patients developed resistance to 5-azacitidine while on therapy. The mechanism of resistance to 5-azacitidine and other hypomethylating agents in vivo are not well characterized. It is possible that secondary resistance to these agents may be due to defects in DNA incorporation and induction of hypomethylation as well as upregulation of apoptosis inhibitors. 10 Several limitations are worth discussing regarding the present study. First, we have not performed specific gene methylation studies. The study of specific genes has the potential to identify suitable molecular markers of response. As this has proved challenging in patients with solid tumors, in patients with hematologic malignancies, several genes have been showed to portend important prognostic value, such as p73, p57
Kip2 , p14
ARF , p15 INK4b , p16
INK4a and others. [20] [21] [22] [23] [24] Methylation status of several genes in patients with MF has been previously reported. A subset of patients with MF was found to have strong hypermethylation in the calcitonin gene 5 0 area 25 and in approximately 90% of cases, hypermethylation of the RARbeta2 gene has been demonstrated using methylation-specific PCR. 7 By contrast, a recent methylation analysis of the promoter region of the tumor-associated genes p14
ARF , p15 INK4b , p16 INK4a , Rb, hMLH1, hMSH2, APC and DAPK in 30 patients with MF has shown that methylation of these genes is a rare occurrence, which suggests that methylation of cell cycle control genes is highly unlikely to drive the pathogenesis of MF at diagnosis. However, hypermethylation of p15
INK4b and p16
INK4a has been frequently observed in patients with MF in transformation to acute myeloid leukemia. 8 A second potential pitfall pertains to the choice of DNA methyltransferase inhibitor employed in this trial. Besides 5-azacitidine, the hypomethylating agent 5-aza-2 0 -deoxycitidine has also been approved by the Food and Drug Administration for the treatment of patients with MDS in the USA due to its remarkable activity in that setting. 13 In the present study, we have employed the same 5-azacitidine dose schedule approved for the treatment of patients with MDS (that is, 75 mg/m 2 daily, for 7 days, every 4 weeks). It is possible that modified dose schedules or the use of 5-aza-2 0 -deoxycitidine instead of 5-azacitidine may render higher response rates and/or longer response duration and, therefore, this aspect warrants further investigation in MF. Furthermore, most patients treated in this study had received other therapies before 5-azacitidine and the use of hypomethylating therapy in the frontline setting may warrant further investigation.
In summary, therapy with 5-azacitidine in patients with MF is relatively well tolerated and is associated with induction of global hypomethylation. However, 5-azacitidine therapy results in limited clinical activity in this patient population.
